Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(7 sites)

United States

City of Hope Comprehensive Cancer Center, Duarte, California

University of California Davis Comprehensive Cancer Center, Sacramento, California

Moffitt Cancer Center, Tampa, Florida

Northwestern University, Chicago, Illinois

Wake Forest University Health Sciences, Winston-Salem, North Carolina

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

University of Virginia Cancer Center, Charlottesville, Virginia